Medicine details

ImageAltrip
NameAltrip
DosageTablet
Generic NameAlmotriptan
Classes Analgesic / Pain Killer
Central Nervous System Agent
Antimigraine Agent
Diseases CNS Disorder
Headache
Light Sensitivity
Nausea
CompanyNIPRO JMI Company Ltd.

Drug Package Details

Strength6.25 mg
Storage Condition
Origin CountryBangladesh
Commercial Pack10
Price per pack250.80
Cost per pack220.70
Package unit10 tabs strip
Price per unit25.08
Cost per unit22.07
Discount0
Coupon
Remarks

Almotriptan

Almotriptan is a 5-HT1B/1D receptor agonist used to treat migraine. Almotriptan's therapeutic activity in migraine is most likely due to agonist effects at 5-HT1B/1D receptors on extracerebral, intracranial blood vessels that dilate during a migraine attack, as well as nerve terminals in the trigeminal system. When these receptors are activated, cranial vessels constrict, neuropeptide release is inhibited, and transmission in trigeminal pain pathways is reduced.

Almotriptan indicated for the acute treatment of migraine with or without aura in adults. 

In controlled clinical trials, single doses of almotriptan Tablets of 6.25 mg and 12.5 mg were effective for the acute treatment of migraines in adults, with the 12.5 mg dose being more effective.

The most common side effects associated with almotriptan are-

  • Nausea
  • Sleepiness/ drowsiness
  • Tingling or burning feeling (paresthesia)
  • Headache
  • Dry mouth
  • Almotriptan should only be used where a clear diagnosis of migraine has been established. 
  • Almotriptan should not be given to patients with documented ischemic or vasospastic coronary artery disease because this class of compounds (5-HT1B/1D agonists) has the potential to cause coronary vasospasm.
  • As with other 5-HT1B/1D agonists, sensations of tightness, pain, pressure, and heaviness in the precordium, throat, neck, and jaw have been reported after treatment with almotriptan.
  • Within a few hours of receiving almotriptan, serious adverse cardiac events, including acute myocardial infarction, have been reported.
  • Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have been reported in patients receiving other 5-HT1 agonists, with some resulting in death.
  • Significant increases in systemic blood pressure, including hypertensive crisis, have been reported in patients with and without a history of hypertension treated with other 5-HT1 agonists on rare occasions.
  • Triptans, including almotriptan, have been linked to the development of a potentially fatal serotonin syndrome.

Contraindication

  • Almotriptan is contraindicated in patients who are hypersensitive to almotriptan or any of its ingredients. 
  • Almotriptan should not be administered within 24 hours of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-type medication like-

Almotriptan should not be given to patients with-

  • ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's variant angina, or other significant underlying cardiovascular disease.
  • uncontrolled hypertension.
  • hemiplegic or basilar migraine.